Pfizer Expects Lung Cancer Drug Lorbrena to Hit Over $1 Billion in Sales After Exceptional 5-Year Data
Pfizer has announced that its lung cancer drug, Lorbrena, is projected to generate over $1 billion in annual sales by 2030, driven by positive clinical trial results. Pfizer Anticipates $1 Billion Annual Sales of Lorbrena According to Reuters, data …